ADMA BIOLOGICS, INC. (ADMA) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, ADMA BIOLOGICS, INC.'s filing signal continuing positive.

ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immune-compromised patients and those at risk for infectious diseases. The company currently markets three FDA-approved products: ASCENIV and BIVIGAM, both intravenous immune globulin (IVIG) products for Primary Humoral Immunodeficiency (PI), and Nabi-HB for Hepatitis B exposure. ADMA operates its own FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, with a peak annual processing capability of 600,000 liters. The company also operates plasma collection centers through its ADMA BioCenters subsidiary, providing a vertically integrated supply chain. ADMA is actively developing a pipeline of plasma-derived therapeutics, including an S. pneumoniae hyperimmune globulin program (SG-001).

Revenue is primarily driven by sales of ASCENIV and BIVIGAM, its intravenous immune globulin (IVIG) products for Primary Humoral Immunodeficiency (PI). Additional revenue is generated from the sale of Nabi-HB, plasma collection, and contract manufacturing services.